Machine Learning Identifies Microbiome and Clinical Predictors of Sustained Weight Loss Following Prolonged Fasting

Gelsomina N. Kaufhold[1,2,3,*], Theda U. P. Bartolomaeus[1,2,3,4,*], Kristin Kräker[1,2,3,4], Till Schütte[1,2,3,4],

Sakshi Kamboj[5], Ulrike Löber[1,2,3,4], Gabriele Rahn[1], Victoria McParland[1,3,6], Lena Braun[1],

Lajos Markó[1,2,3,4], Matanat Mammadli[1,2,3], Alexander Krannich[7], Lina S. Bahr[1,2,3],

Friederike Gutmann[1,2,3,4], Friedemann Paul[1,2,3], Nicola Wilck[1,3,4,6], Alma Zernecke[8], Peter J. Oefner[5],

Wolfram Gronwald[5], Dominik N. Müller[1,2,3,4], Sofia K. Forslund-Startceva[1,2,3,4,9], Sylvia Bähring[1,2,3,†],

Hendrik Bartolomaeus[3,4,8,†], Nadja Siebert[1,2,3,†]

[1]Experimental and Clinical Research Center (ECRC), a cooperation of Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany

[2]Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

[3]Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany

[4]DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany

[5]Institute of Functional Genomics, University of Regensburg, Regensburg, Germany

[6]Department of Nephrology and Internal Intensive Care Medicine, Charité –Universitätsmedizin Berlin, Germany.

[7]BioStats GmbH, Nauen, Germany

[8]Institute of Experimental Biomedicine, University Hospital Würzburg, Germany.

[9]Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.

*contributed equally

†jointly supervised the work

Correspondence: bartolomae_h@ukw.de

Abstract

Prolonged fasting may benefit metabolic health, but data in healthy individuals remain limited. We performed a randomized, waitlist-controlled study (LEANER study), with 38 healthy participants completing a 5-day-fasting intervention with 12-week follow-up. Fasting acutely lowered body mass index (BMI), via fat mass loss. These changes partially persisted at follow-up. Fasting altered the gut microbiome composition and induced metabolite shifts in plasma and feces. Changes to gut microbiome alpha diversity after fasting correlated with baseline microbiome diversity. Long-term BMI response at follow-up could be predicted through machine learning (ML) using baseline microbiome and clinical data, highlighting an unknown *Faecalibacterium* sp., *Oscillibacter* sp. 50_27, LDL cholesterol, and systolic blood pressure as key predictors. This ML model was validated in independent patient cohorts with metabolic syndrome and multiple sclerosis. These findings support prolonged fasting as an effective metabolic intervention and demonstrate that individual responses to fasting interventions can be predicted using pre-intervention features.

Introduction

Fasting interventions have gained renewed attention for their potential to modulate metabolism, reshape the gut microbiome, and promote healthy aging[1]. While fasting protocols vary widely from time-restricted eating to fasting-mimicking diets[2], and prolonged food abstinence lasting up to several weeks (up to 26 days)[3], the underlying principle is consistent: transient caloric deprivation triggers coordinated physiological responses that may confer long-term health benefits[4].

Evidence from patient populations, including those with metabolic syndrome[5], autoimmune diseases[6,7], and cancer[8], suggests that fasting can influence key regulatory pathways such as autophagy, insulin sensitivity, and oxidative stress[1]. In individuals with metabolic syndrome, we previously demonstrated that a 5-day fast atop a DASH (Dietary Approaches to Stop Hypertension) diet induced profound and coordinated changes in gut microbiome composition and immune cell states most of which were reversed at 12 weeks follow-up[5]. Using immune cell population or microbiome profiles, we developed models that predicted long-term antihypertensive effects, supporting the concept of data-driven stratification[5].

In parallel, gut microbiome profiling has emerged as a powerful tool for personalized medicine[9]. Microbial signatures have been linked to energy metabolism[10], weight regulation[11,12], and immune modulation[13,14]. Personalized dietary approaches that account for microbiome composition have demonstrated superior outcomes in metabolic control[8]. Emerging applications extend to autoimmune, neuropsychiatric, and oncologic indications, underscoring the potential of microbiome-informed strategies in precision medicine[9,15].

Despite these advances, the long-term effects of prolonged fasting in healthy individuals remain poorly characterized. Most existing studies rely on non-randomized designs, lack adequate control groups, or fail to include follow-up assessments. Furthermore, many

interventions are performed in multimodal clinical settings involving exercise, psychological

support, and dietary coaching[5], making it difficult to isolate the effect of fasting alone.

Here, we present a randomized, waitlist-controlled study investigating the effects of a 5-day

prolonged fasting intervention in healthy adults, with follow-up assessments at 12 weeks. We

integrated clinical, microbiome, and metabolome profiling to characterize immediate and

long-term physiological responses. Using machine learning, we show that sustained weight

loss can be predicted from baseline microbiome and clinical features. The results that were

validated in independent cohorts with metabolic syndrome and multiple sclerosis. Our

findings offer mechanistic insight into fasting responses and support the potential of

microbiome-informed strategies for personalized lifestyle interventions.

Results

Prolonged fasting affects energy expenditure and long-term weight loss

Thirty-eight healthy participants were recruited for a 5-day prolonged fasting intervention

(Figure 1a). As fasting interventions cannot be blinded, we decided to use a waiting list

control to account for physiological fluctuations within a 12-week timeframe while

maximizing the number of participants undergoing prolonged fasting (Figure 1A). Baseline

characteristics are shown in Table 1.

Of the 38 participants, 83% reported fasting-related adverse events (AE) (Table S1). All AE

were mild and transient and did not necessitate discontinuation of fasting. Blood glucose and

β-hydroxybutyrate levels were measured each morning and evening during the five-day

fasting period (days 1–5), confirming that all participants adhered closely to the study

protocol (Figure S1a, b). We observed a diurnal rhythm with higher BHB but lower glucose

concentrations in the morning compared to the evening (Figure S1a, b). Continuous

interstitial glucose monitoring during the five-day fasting period, compared with baseline

measurements and waiting-list controls, confirmed a dynamic reduction in glucose levels

over the course of the fast. (Figure 1b). Following refeeding the glucose levels normalized;

however, between days 2 and 4 post-fast, blood glucose concentrations were elevated

throughout the day (06:00–22:00) compared with baseline measurements (Figure 1c).

Our predefined endpoint was a change in resting energy expenditure (REE). Prolonged fasting

acutely reduced REE by 62 kcal/d, suggesting a fasting-induced, energy-preserving

mechanism (Figure 1d, Supplementary Data 1). We did not observe alterations in REE

between the two baseline timepoints of waiting list controls (Figure 1d). Since REE was the

defined endpoint, we performed a linear mixed model showing that lean mass (p < 0.001)

and not self-reported sex significantly influenced REE at all visits, including post-fasting

(Figure S2). Following the five-day fast, respiratory exchange ratios (RER) declined

significantly (Figure 1e), paralleling a peak in BHB concentrations on day 5 (Figure S1b). All

those metabolic makers returned to baseline by 12 weeks post-fast.

Furthermore, we observed that prolonged fasting reduced BMI (Figure 1f). This decrease was

partly reversed after 12 weeks follow-up (Figure 1f). Body composition analysis attributed

this incomplete return towards baseline BMI predominantly to a reduction in fat mass

(Figure 1g, S1g). Of note, the absolute and relative reduction of body fat was accompanied

by a reduction in lean mass during fasting that completely reverted at follow-up (Figure S1h).

Prolonged fasting reduced waist-to-hip ratio and diastolic blood pressure while increasing

heart rate, findings which are consistent with a previously published study in metabolic

syndrome (Figure S1d-g). In contrast to metabolic syndrome patients[5], the healthy

participants in this study did not exhibit sustained blood-pressure reductions (Figure S1e, f).

Taken together, these results demonstrate that prolonged fasting is well tolerated in healthy

individuals, yielding sustained reductions in BMI and fat mass, while most metabolic and

hemodynamic parameters return to baseline during the 12-week follow-up.

Prolonged fasting induces large short-term and small long-term changes in gut microbiome

composition

To assess the natural fluctuation of the gut microbiome composition, we analyzed changes

between the two baseline samples (baseline 0 and baseline 1) from the waiting list control

(Figure 1a). Microbial alpha diversity, measured as Shannon index, and microbiome

composition quantified by Bray-Curtis dissimilarity did not differ significantly between the

two baseline samples (Figure S3a, b). Shannon index remained stable across all study visits

(Figure 2a). In contrast, individual trajectories in response to fasting varied markedly (Figure

2a). Interestingly, short-term (post-fasting) and long-term (follow-up) changes in alpha-diversity correlated negatively with alpha-diversity at baseline, implicating baseline differences in microbiome composition as relevant predictors of fasting-induced microbiome changes (Figure 2b, c). Bray-Curtis dissimilarity-based multivariate analysis of the taxonomic composition demonstrated a significant shift in microbial community composition in response to fasting that partially reversed during the follow-up period (Figure 2d). Consistent with the observed shift in the multivariate analysis, fasting induced significant changes in several bacterial species that reversed during follow-up. For example, *Roseburia* sp. inserta sedis and *Bifidobacterium adolescentis* decreased after the fasting period but increased at follow-up, whereas *Faecalibacterium* sp. CAG-74 showed the opposite pattern (Figure 2e, S3c, Supplementary Data 2). In contrast, only seven taxa exhibited sustained abundance changes (Figure S3c).

Next, we analyzed gut-specific metabolic modules using GOmixer. Again, fasting induced pronounced alterations that largely reverted to baseline during follow-up (Figure 2f). Only for three modules, ketone body synthesis, osmoprotectant transport system, and N-acetylneuraminate and N-acetylmannosamine degradation, fasting induced a long-lasting increase when comparing baseline to follow-up (Figure 2f, Figure S4a, Supplementary Data 3).

Overall, prolonged fasting induces pronounced compositional shifts in the gut microbiome which were largely reversed upon refeeding, resulting in minimal long-term deviations from baseline at the 12-week follow-up. Notably, baseline alpha diversity metrics correlate with the magnitude of alpha diversity changes both immediately after fasting and at follow-up.

Prolonged fasting alters plasma and fecal metabolome

We performed nuclear magnetic resonance (NMR) spectroscopy on plasma and fecal

samples to assess the impact of fasting, and its associated microbiome shifts on the fecal and

host metabolome. Principal coordinate analysis (PCA), centered on baseline values to

characterize post-fast changes and on post-fast values to characterize follow-up effects,

revealed plasma metabolome trajectories analogous to those observed in the gut

microbiome (Figure S4b). In line, we observed significant alterations between baseline,

fasting, and follow-up, with most changes reversed at follow-up (Figure S4c, Supplementary

Data 4). In plasma, only valine, glycine, tyrosine, and pyruvic acid exhibited sustained

increases from baseline to follow-up, indicating lasting effects of fasting on these metabolites

(Figure S4b, c).

Fecal metabolite profiling again revealed a pattern of alteration and reversion to baseline

(Figure S4d). Contradicting other previous reports on short-chain fatty acids (SCFA) in

fasting[5], we observed a decrease in butyrate during fasting, which was non-significant at

follow-up (Figure S4e, Supplementary Data 5). The only long-term effect observed in our data

was a decrease in choline from baseline to fasting (Figure S4e).

In conclusion, NMR-based metabolomics of plasma shows more consistent alterations as

compared to the fecal metabolome, which might be due to the different matrix or

intraindividual variations in gut microbiome composition.

Prediction of sustained BMI response by multi-omics machine learning

Since we observed strong intraindividual differences in response to prolonged fasting across

most data layers, we aimed to investigate whether the clinical response to fasting can be

predicted from baseline data. Since BMI showed the overall strongest long-term effect of the

analyzed clinical data (Figure 1), we focused on the long-term weight loss phenotype. Using

the waiting list control, we estimated the normal fluctuation of BMI within 12 weeks of study

participation. Normal fluctuation in BMI was defined as mean ± two standard deviations

(SD)[16], in our case -0.008 ± 0.32 kg/m^2. With this threshold, we identified 38% BMI long-term

responders and 62% BMI non-responders to prolonged fasting. In order to cross-validate our

model in publicly available datasets we focused on microbiome and clinical features over

NMR metabolomics[5,17]. A random forest classifier was trained on 87 features including the 50

most abundant species, candidate species and pathways from previous studies on prolonged

fasting, as well as relevant clinical metadata (Supplementary Data 6) using 80% of our data.

To account for the small sample size, we used leave-one-out cross-validation. The model was

evaluated on the remaining 20% of the dataset that was held out during training (Figure 3a).

The initial model achieved 66.7% accuracy with 100% sensitivity in identifying responders in

the test dataset. To optimize performance, we then selected key predictors using random-

forest feature importance, the Boruta algorithm, and backward feature elimination

(Figure 3b, S5c). This analysis indicated four key predictors: LDL, systolic blood pressure (BP),

Faecalibacterium sp. incerta sedis and *Oscillibacter* sp. 57_20. Those four features were used

to train the final model on 80% of the dataset. The refined model demonstrated improved

performance, achieving 83.3 % accuracy, an 80% positive predictive value, and a 100%

negative predictive value (Figure S5a).

Baseline BMI can confound weight loss predictions, so we tested for collinearity and

correlations between baseline BMI and our four selected features none of which reached

significance (Figure 3c). To further test if our four features are mere surrogate markers of

baseline BMI, we incorporated baseline BMI into the model which did not improve predictive

accuracy (Figure S5b). Furthermore, *Oscillibacter* sp. 57_20 remained the most important

feature. These results confirm that our final model captured biologically relevant signals

beyond simple baseline BMI effects.

Finally, we examined the abundance patterns of the model's key features within our cohort.

Responders exhibited significantly higher levels of *Oscillibacter* sp. 57_20 (Figure 3d), while

the identified *Faecalibacterium* sp. showed no significant difference (Figure 3f). Although

important for responder identification, we observed no significant differences in systolic

blood pressure or plasma LDL levels between responders and non-responders (Figure 3e, g).

Taken together, we identified four (two clinical and two microbiome) features that hold the

potential to predict long-term weight loss in response to prolonged fasting interventions.

Although our model performed robustly on the 20 % hold-out set, these results were

achieved in a very limited cohort size.

Validation in available datasets of patients with co-morbidities

To address this limitation, we next applied our model to our published metabolic syndrome

cohort in which patients underwent either a five-day fasting regimen followed by a DASH

diet or a DASH diet alone (Figure 4a)[5]. The study outcomes were assessed 12 weeks post-

intervention, mirroring our study's timeline. Given the greater BMI variability expected in

metabolic syndrome patients, we again quantified BMI fluctuation from the DASH only group

and subsequently defined long-term responders with a BMI reduction exceeding 0.8 kg/m^2.

Remarkably, our trained model predicted sustained weight loss in this study with an AUC of

0.85 (Figure 4b). Our model correctly classified 19 (82.6% [61.2 – 95.1%] accuracy) of the 23

patients and with a sensitivity and specificity of 85.7 % and 81.3 %, respectively (Figure 4b).

Furthermore, patients classified as responders showed a significantly higher BMI reduction at

12 weeks follow-up compared to non-responders (Figure 4c, d). Consistent with our

healthy-participant cohort, the model's predictive features exhibited only weak correlations

with baseline BMI, underscoring their independence from initial body mass (Fig. 4e). In

univariate analyses, none of the features differed significantly at baseline between

responders and non-responders (Figure 4f-i).

As further validation, we selected a recent nutritional intervention trial in multiple sclerosis

patients, the majority of whom exhibited normal metabolic profiles (obesity in one patient,

hypertension in two patients, high LDL in four patients) [17]. Notably, the study design differed

substantially. Patients completed two prolonged fasting cycles, interspersed with an interim

period of intermittent fasting (14 hrs/ day), and follow-up assessments were conducted nine

months apart (Figure 5a). As the control arm of this study included dietary counseling,

following the dietary recommendations of the German Society of Nutrition, we did not use it

to define average BMI shifts over nine months. Therefore, we could not calculate specificity

or sensitivity. Nevertheless, patients classified as responders by our model experienced

significantly greater weight loss than those classified as non-responders (Figure 5b). Again,

no significant correlations between model parameters and baseline BMI were detected in

this cohort (Figure 5c). Similar to the current cohort, levels of *Oscillibacter* sp. 50_27 were

significantly higher in responders (Figure 5e. The other features did not differ significantly

(Figure 5f-h).

Our findings indicate that baseline patient characteristics determine the magnitude of long-

term weight response to prolonged fasting interventions. Furthermore, the predictive model,

initially developed in healthy subjects, retained robust performance when applied to both

individuals with metabolic syndrome and to a regimen involving two separate prolonged-

fasting episodes.

249 *Metabolite associations with Oscillibacter sp. 57_20 and Faecalibacterium sp. incertae sedis*

250 Since both the *Oscillibacter* sp. 57_20 and the *Faecalibacterium* sp. identified in this study

251 were predictive of weight loss, we wanted to further understand the potential metabolite

252 profile associated with these bacteria. Therefore, we performed an exploratory correlation

253 analysis with the fecal metabolome across all visit data while blocking the visit information[18].

254 We found significant associations of *Faecalibacterium* sp. with butyrate, tryptophan, and

255 uridine (Figure 6a-c, Supplementary Data 7) as well as of *Oscillibacter* sp. 57_20 with glycerol

256 and methionine, and for uridine without reaching statistical significance (Figure 6d-f,

257 Supplementary Data 8). In summary, our data suggest that the bacterial species important

258 for the classification of long-term body weight responders modulate the metabolomic output

259 of the fecal microbiome.

Discussion

Our data show that prolonged fasting leads to long-term body weight and body fat reduction after 12 weeks. Interindividual variability in response to dietary interventions poses a major challenge in lifestyle interventions. Large-scale studies have shown that both host and microbial factors shape individual metabolic responses, emphasizing the need for precision strategies[19,20]. Using baseline microbiome and clinical data, we can predict individuals who will respond to fasting with sustained weight loss, defined as a BMI reduction lower than the mean minus two standard deviations of the waiting list control. Using available data from similar interventions in patients with metabolic syndrome and patients with multiple sclerosis, we could validate our data-driven classification approach. While *Faecalibacterium* sp. incertae sedis and *Oscillibacter* sp. 57_20, were important for BMI response prediction, most of the microbiome and metabolome features were characterized by transient shifts induced by fasting, with subsequent return to pre-intervention states. Taken together, our data implicate gut microbiota in long-term BMI changes post fasting and suggest conserved effects of fasting regardless of health status.

On host level, prolonged fasting led to strong changes of multiple cardiometabolic risk factors like LDL cholesterol, waist-to-hip ratio, and systolic and diastolic blood pressure. However, at 12 weeks follow-up these changes mainly reverted, indicating that prolonged fasting does not exert a sustained effect in healthy individuals. These data differ from in patients with metabolic syndrome with values above the healthy range[5]. Interestingly, while blood glucose dropped during fasting, it increased upon refeeding during the day (6am to 10pm). Since values at night (10pm to 6am) did not increase, our data suggest a mildly disturbed glucose handling for the early days post-fasting. A similar phenotype was reported in the literature in response to standardized meal intakes after prolonged fasting[21,22]. This was attributed to the

metabolism successfully switching to fatty acid and ketone oxidation and postprandial

carbohydrate oxidation was reduced leading to higher plasma glucose levels[21]. Since a strong

metabolic phenotype was expected, REE reduction was our predefined endpoint. REE in

fasting was studied previously mainly in healthy men[23-25] Our data shows an overall similar

but smaller effect, which might be due to the inclusion of healthy women and a broader

range of lean masses. Levels of REE reduction after 24h caloric deprivation was previously

associated with weight gain after 6 months in healthy individuals[26]. We could not confirm

these findings in our cohort for long-term weight changes after 3 months using the changes

in REE after 5 days of fasting (Figure S6). However, using a combination of clinical and

microbiome data, we were successful in predicting long-term weight loss.

We have shown in the past the microbiome and immune data can predict blood pressure

reduction in patients with metabolic syndrome in response to fasting[5]. In contrast, our study

in healthy participants revealed only modest effects on blood pressure. Given the well-

established impact of fasting on weight managemen[27], we applied a data-driven approach

that involved clustering participants based on BMI changes and employing a random forest

classifier. Our initial model, which incorporated 83 features, demonstrated high sensitivity

but limited specificity, iterative feature selection enabled us to identify *Faecalibacterium* sp.

incertae sedis, *Oscillibacter* sp. 57_20, plasma LDL levels, and systolic blood pressure as key

predictors. Notably, independent validations highlighted the robustness and generalizability

of our approach. In the Maifeld et al. cohort[5], which featured a similar study design in

patients with metabolic syndrome, we observed an 82.6% of responders were correctly

identified. In the Bahr et al. cohort[17], with a different study design incorporating intermittent

fasting in patients with multiple sclerosis, predicted responders exhibited higher weight loss.

These external validations not only reinforce the reliability of our predictive model but also

suggest that the gut microbiome changes associated with fasting responses are conserved

across diverse populations, from healthy individuals to those with metabolic disorders and

autoimmune disease, thereby broadening the potential applicability of fasting-based

interventions for weight management and metabolic health.

Given that baseline BMI is typically a key predictor of weight loss, we assessed its

confounding effect on fasting-induced BMI changes. *Oscillibacter* sp. 57_20 remained the

stronger predictor even when baseline BMI was included in the model, indicating that this

microbial species may exert an independent influence on weight regulation during fasting.

While we cannot fully exclude potential confounding or correlations between baseline BMI

and microbiome composition, to our knowledge, no prior study has directly linked

Oscillibacter sp. 57_20 with weight regulation. However, *Oscillibacter* sp. 57_20 was recently

identified as a keystone taxon in a similar prolonged fasting study in healthy individuals,

where it was implicated in the production of indole-3-propionate (I3P)[28], a protective

metabolite in cardiometabolic disease[29]. Future research is needed to explore the

mechanistic role of *Oscillibacter* spp. in host metabolism and its potential relevance in

personalized fasting interventions.

Faecalibacterium spp. are known SCFA producers[30]. In line, our data shows that the

abundance of our specific *Faecalibacterium* sp. associates with fecal butyrate levels. As

described previously for other *Faecalibacterium* spp.[31], the identified *Faecalibacterium* sp.

correlates with fecal tryptophan. Tryptophan can be catabolized by gut microbiota to indole

metabolites[32]. Unfortunately, due to the resolution of NMR metabolomics, we could not

detect specific indole metabolites like I3P. However, our data implicate that both bacteria

might interact in the production of tryptophan catabolites.

Both the *Faecalibacterium* sp. identified in this study and the *Oscillibacter* sp. 57_20

correlate with the nucleoside uridine. Uridine can adaptively regulate food intake in healthy

participants[33]. Furthermore, experimental evidence show that blood uridine levels reflect the

nutritional status of mice[34,35] with high uridine levels as indicators of catabolic states[34,36]. In

line, dietary supplementation of uridine enhanced hunger and increased caloric intake[33].

Microbial metabolism of uridine suggests a potential role of a gut-brain axis or influence on

satiety[37] in long-term BMI responders. Unfortunately, the literature concerning the other

metabolites of interest correlating with *Oscillibacter* sp. 57_20, glycerol and methionine is

sparse. While we controlled our analysis for abundance shifts at different visits, we could not

control the false discovery rate in this exploratory setting. Future confirmatory studies are

needed to further investigate the metabolite spectra of the identified *Faecalibacterium* sp.

and *Oscillibacter* sp. 57_20.

Overall, the gut microbiome and metabolome exhibited a consistent pattern of fasting-

induced alterations and nearly complete reversion to baseline at follow-up. Previous studies

have consistently reported an enrichment of beneficial bacteria such as *F. prausnitzii* [38-40], as

well as *Roseburia* and *Coprococcus* species, other known SCFA producers[41-43]. Our data only

partly overlaps with these reports, as we observed no alterations to *F. prausnitzii*, alongside a

decrease in *Roseburia* spp. and *Coprococcus* spp. However, we observed an increase in one

Butyricicoccus sp., known butyrate producers. Our functional analysis revealed an increase in

propionate production via kinase pathways, pointing towards an elevated SCFA production

potentials from coordinated activity across broader microbial community rather than single

species effects. The discrepancy with earlier findings may be attributed to our study's healthy

cohort, in which baseline levels of F. prausnitzii are likely already well-balanced. This suggests

that fasting might predominantly restore disturbed bacterial populations rather than altering

already stable communities. Suggest that fasting primarily restores imbalanced microbial

populations, rather than reshaping already stable communities.[44] Interestingly and consistent

previous studies, we did not observe overall change in alpha diversity[5,42]. However,

participants with lower baseline alpha diversity responded with a long-lasting increase to the

fasting intervention. High microbial diversity stabilizes microbiota functions during

perturbations[45]. In diseases usually associated with lower alpha diversity, such as obesity,

other fasting interventions increase alpha diversity[46]. Together, these studies reinforce the

hypothesis that fasting effects on alpha diversity are more pronounced in individuals with a

reduced microbial diversity. However, low baseline alpha diversity may also arise from

unaccounted external influences (e.g., lifestyle habits immediately preceding the

measurement).

Despite these promising results, our study has several limitations. First, the lack of

comprehensive documentation on dietary intake following the fasting intervention. Whether

significant weight loss was solely due to fasting or also influenced by subsequent dietary

modifications, a common limitation in caloric restriction studies, cannot be determined.

From a computational perspective, the relatively small sample size, particularly the initial test

dataset after splitting, poses challenges for the random forest model and feature selection[47].

However, the validation in two independent cohort shows the robustness of our approach[48].

In conclusion, our study provides compelling evidence that fasting induces substantial yet

reversible changes in the gut microbiome and host metabolic profiles. Importantly, a subset

of individuals experiences sustained weight loss. The integration of microbial and clinical

data not only enhanced our predictive capabilities but also unveiled novel associations, such

as the independent role of *Oscillibacter* sp. 57_20 and *Faecalibacterium* sp. incertae sedis in

weight regulation. Despite limitations related to dietary documentation and sample size,

these findings pave the way for future research aimed at refining personalized fasting

interventions. Ultimately, our work underscores the promise of leveraging gut microbiome

insights to tailor dietary strategies for improved metabolic health and weight management.

Methods

Study design

We performed a randomized, waitlist-controlled study (LEANER study, ClinicalTrials.gov;

NCT04452916) carried out at the Experimental and Clinical Research Center of Charité –

Universitätsmedizin in Berlin, from November 2020 to December 2022. The study protocol

was approved by the institutional review board of Charité – Universitätsmedizin Berlin

(EA1/033/20) and all participants provided written informed consent before entering the

study. We collected and managed study data using REDCap electronic data capture tools

hosted at Charité – Universitätsmedizin Berlin[49,50]. This study was exploratory, and we did not

calculate a pre-determined sample size. Instead, the size of the recruited cohort was

determined based on methodological and feasibility considerations. A general overview of

the study is provided in Fig. 1a.

Eligibility criteria

We included individuals aged 20-50, who were assigned male or female at birth and

identified as men and women, respectively; with a body mass index between 20-30 kg/m^2.

Exclusion criteria were heart, lung, liver, and kidney diseases requiring medical intervention,

prescribed medication (except oral contraceptives), postoperative phases, current or chronic

infection, antibiotic treatment or a fasting week within the last 6 months, habitual use of

dietary supplements, food intolerances, > 2 kg body weight change within the last month,

pregnancy, lactation, vegan diet, smoking, drug, or alcohol abuse.

Intervention

Participants received oral and written instructions on the method of prolonged fasting.

Expert guidance was provided by experienced nutritionists and certified fasting counselors in

a group setting with 5-10 participants per group. After sufficient instruction, the fasting was

performed individually at home, with the possibility of reaching out to the counselor at any

time or to connect with other group members (if patients gave consent to share this

information). Participants were encouraged but not required to take time off during this

week. Fasting was preceded by one preparation day, on which participants consumed a low-

calorie, fiber-rich diet, e.g. fruits, vegetables, potatoes, rice, oats.

During the five fasting days, participants were allowed to consume 200-250 kcal/d through

vegetable juices and vegetable broths. Herbal teas and water could be consumed ad libitum.

At the morning of fasting day 6, we performed the study visit and patients were instructed

for the refeeding phase. A detailed fasting plan including refeeding recommendation is

provided as Supplementary Table S2.

Randomization

We assigned participants randomly according to a locked list created by www.randomizer.at

(two treatments: waiting, fasting; 1 factor: self-reported sex; permuted blocks; block sizes 4,

2, 6, 4). Due to the nature of the intervention and the wait-list design, blinding was not

possible.

Outcome measures

We established all outcome measures in advance and did not adapt them during or after the

study. The primary outcome measure was resting energy expenditure (REE in kcal/d) after 5

days of fasting vs. baseline 1 assessed by indirect calorimetry. Secondary outcomes were

body composition, cardiovascular parameters, various routine blood parameters, glucose

variability, gut metagenome, fecal and plasma metabolome. In addition, we assessed

compliance and safety of fasting.

Study center assessments

The waiting group underwent assessments four times, the fasting group three times. The

fasting group had one baseline visit (baseline 1) and started the intervention within two to

eleven days afterwards, the waiting group had two baseline visits with a 12-week waiting

period in between (baseline 0 and baseline 1) and also started the intervention within a

maximum of 11 days after baseline 1. These two baselines allowed detection of random time

effects on the assessed outcome measures. For both groups, the next visit was on the

morning of the sixth fasting day directly before breaking the fast (fasting). To assess medium-

term effects of fasting, there was another visit after 12 weeks (follow-up). Except for the

additional baseline 0 in the waiting group, all assessments were identical between the

groups. All examinations described hereafter were performed at all study visits.

Assessments commenced in the morning following a 12-hour overnight fast. Participants

were instructed to abstain from caffeine, alcohol, and vigorous exercise for 24 hours prior to

the assessments.

Venous blood was drawn and sent to an accredited laboratory (Labor Berlin, Berlin,

Germany) that measured parameters of glucose and lipid metabolism, blood count,

electrolytes, liver enzymes, uric acid, CRP, and renal function according to international

standards.

We measured waist and hip circumference to calculate waist-to-hip ratio and determined

body composition (lean and fat mass) by air displacement plethysmography (Bod Pod, Life

Measurements, Inc., Concord, CA).

Indirect calorimetry was conducted following a 30 min resting period while in a supine

position within a thermoneutral environment for a duration of 30 min (Quark RMR, COSMED,

Italy). REE and respiratory exchange ratio (RER) were calculated from oxygen consumption

and carbon dioxide production as described elsewhere.[51]

Office blood pressure and heart rate were determined by five automated measurements

within 10 min with an upper arm cuff (Mobil-o-Graph, I.E.M. GmbH, Stolberg, Germany) in

the absence of study personnel.

Fecal samples

At each study visit, participants received two stool collection kits and were asked to collect

two samples from one stool at home as soon as possible following the study visit. One

sample was used for gut metagenome sequencing (OMNIgene Gut, DNA Genotek, Ottawa,

Canada) and the other for metabolome analysis (OMNImet Gut, DNA Genotek, Ottawa,

Canada). These kits allow shipment without cooling to the study center. Participants sent the

tubes to the study center at room temperature, where they were stored at - 80℃ until

further processing.

Glucose sensors

We assessed glucose variability by continuous glucose monitoring over 14 days. For this,

participants wore a glucose sensor that measured interstitial glucose concentrations in the

subcutaneous tissue of the dorsal upper arm every 15 min (FreeStyle Libre Pro, Abbott,

Chicago, IL, USA). In contrast to the use of these sensors in diabetic patients, participants in

this study could not see their values during the measurement. Baseline assessment was done

only in the waiting group directly following baseline visit 0. Additionally, fasting assessment

was done in all participants during preparation, fasting and refeeding.

Ketone and glucose measurements

On the five fasting days, participants independently measured their blood concentration of

beta-hydroxybutyrate (BHB) and glucose twice daily using a handheld glucometer (Freestyle

Precision Neo, Abbott, Chicago, IL, USA), and recorded their values in a provided protocol. In

addition, values were stored on the device and read out later in the study center, providing

an objective measure of compliance.

Fecal metagenomic sequencing

DNA isolation

DNA was isolated using ZymoBIOMICS DNA Miniprep Kit (ZymoReseach Europe GmbH,

Freiburg, Germany). In short, an aliquot of 250 µL of stool sample from the OMNIgene Gut

tube was added to a ZR BasingBead Lysis Tube. The following extraction was done according

to the manufacturer's instructions. DNA was eluted in 100 µL RNase/DNase-free water and

collected in a 1.5 mL Eppendorf Tube. Total DNA concentration was measured using

NanoDrop ND-1000 (Peqlab Biotechnologie GmbH, Erlangen, Germany). Isolated DNA was

stored at - 80°C[52].

Shotgun metagenomics

Isolated DNA was shipped on dry ice to Novogene (Cambridge, UK) for shotgun metagenomic

DNA sequencing. In short, DNA was fragmented and subsequently underwent end repair and

phosphorylation. After A-tailing, adapter ligation was performed. Then 150 bp paired-ending

sequencing was performed on the Illumina Novaseq 6000 platform with an aimed data

collection of 6Gb raw data.

Microbiome data processing

Sequencing reads were mapped to the mOTUv2 (version 2.6) database, and read counts

were subsequently rarefied using the RTK R package (version 0.2.6.1) to standardize

sequencing depth across samples. Rarefaction involves randomly subsampling reads to

match the sample with the lowest read depth, thereby mitigating biases introduced by

variable sequencing depth and enabling reliable comparisons across cohorts. For the LEANER

(healthy) cohort, a cutoff of 3,859 reads was applied, resulting in the exclusion of one sample

due to insufficient sequencing depth. The same threshold was used for the Maifeld cohort[5],

where one sample was also excluded. In the Bahr dataset[17], applying the same rarefaction

criteria led to the exclusion of one sample. This consistent approach enabled reliable

comparisons across cohorts and increased the robustness of downstream analyses.

Plasma metabolomics

Collection of plasma

Venous blood was collected in Vacutainer® EDTA tubes (BD, Heidelberg, Germany) and

immediately put on crushed ice for 30 min and then centrifuged (3,000 g, 4°C, 10 min).

Plasma was collected and stored at - 80°C.

Preparation of plasma for nuclear magnetic resonance spectroscopy (NMR)

Plasma samples were prepared with a robotic system (SamplePro Tube, Bruker BioSpin

GmbH, Ettlingen, Germany) by mixing 287 µL plasma with 287 µL IVDr buffer (Bruker BioSpin

GmbH, Ettlingen, Germany) and adding 10 µL formic acid (240 mM) as internal standard.

NMR measurement of plasma

All NMR experiments were performed on a 600 MHz Bruker Avance III spectrometer, using a

triple resonance (^{1}H, ^{13}C, ^{15}N, ^{2}H lock) helium cooled cryoprobe with z-gradient. Samples

were handled by an automatic Bruker SampleJet sample changer (Bruker Biospin GmbH,

Ettlingen, Germany). Tuning and matching of the probe as well as locking and shimming of

the sample were performed automatically. Following the Bruker IVDr protocol for plasma

measurements, for each sample four different types of ^{1}H NMR spectra were acquired at 310

K (1D NOESY, 2D JRES, 1D CPMG, and 1D spin echo diffusion spectrum).

Data analysis of plasma NMR spectra

From the collected spectra of each specimen, 41 smaller, non-lipoprotein metabolites were

automatically identified and quantified using the Bruker IVDr Quantification in Plasma/Serum

B.I.Quant-PS™ platform. Of note, only metabolites levels not bound to proteins were

determined. Additionally, 112 lipoprotein parameters including various lipoprotein fractions,

classes and subfractions were identified and quantified using the Bruker IVDr Lipoprotein

Subclass Analysis B.I.LISA™ platform.

Stool metabolomics

Drying of stool samples

Fecal samples from OMNImet Gut tubes were processed for metabolomics. Fecal samples (1

mL) were dissociated two times after adding 2.5 mL 70% isopropanol using C tubes with the

gentleMACS OctoDissociator (Miltenyi Biotec, Bergisch Gladbach, Germany). Aliquots of

dissociated samples were covered with perforated Parafilm and dried overnight in a vacuum

concentrator (Concentrator 5301, Eppendorf, Hamburg, Germany). Dried samples were

stored at - 80°C.

Preparation of stool for NMR

Dried stool samples were resuspended in 600 µL (< 10 mg dry weight), 800 µL (10-40 mg dry

weight) or 1,000 µL (> 40 mg dry weight) of double distilled water and 10 µL of an extraction

standard (Nicotinic acid at 80 mmol/L) were added. Samples were centrifuged three times

(12 000 x g, 4 °C, 10 min) and supernatants were transferred into a fresh vial after each

centrifugation in order to remove particles. Of the final supernatant, 400 µL were mixed with

200 µL of 0.1 mol/L phosphate buffer (pH 7.4) and 50 µL of a 0.75% (w/v) solution of 3-

trimethylsilyl-2,2,3,3-tetradeuteropropionate (TSP; Sigma-Aldrich, Taufkirchen, Germany),

which served as an internal standard, in deuterium oxide.

NMR measurements of stool

NMR experiments were conducted on the same NMR spectrometer as described for the

plasma analyses. Before measurement, each sample was allowed to equilibrate for 300 sec in

the magnet, and the probe was automatically locked, tuned, matched, and shimmed. One-

dimensional 1H NMR spectra were obtained at 298 K using a nuclear Overhauser

enhancement spectroscopy pulse sequence with solvent signal suppression by pre-saturation

during relaxation and mixing time. For each spectrum, 512 scans were collected into 65,536

data points over a 20-ppm (parts/million) spectral width using a relaxation delay of 4 sec, an

acquisition time of 2.66 sec, and a mixing time of 0.01 sec. Spectra were automatically

Fourier transformed and phase and baseline corrected.

Data analysis of stool NMR spectra

In each spectrum, a set of 41 metabolites were semi-automatically identified and relative to

the TSP reference signal quantified using the CHENOMX 9.02 (Chenomx Inc, Edmonton,

Canada) software suite. To account of potential losses during sample preparation resulting

data was adjusted to the extraction standard and normalized to dry weight.

Statistical analysis

Descriptive statistics for interval variables are presented as mean ± standard deviation or

median with interquartile range (IQR). For comparisons of delta BMI between responders

and non-responders, normality of variable distributions was assessed by visual check of

histograms and qq-plots. Mann-Whitney U-test or T-test was used as appropriate. For all

other data, comparisons between independent groups were performed using the Mann-

Whitney U test, and paired samples were compared using the Wilcoxon signed-rank test.

Where applicable, p-values were adjusted for multiple comparisons using either the Holm

method (for family-wise error control) or the Benjamini-Hochberg (BH) procedure (for false

discovery rate control), depending on the analytical objective.

Permutational Multivariate Analysis of Variance (PERMANOVA) was used to test for

multivariate compositional differences between groups and visits.

To evaluate the relationship between bacterial abundance and metabolite concentrations

while accounting for visit timepoint, we performed permutation-based conditional

independence tests. Specifically, for each metabolite, its association with Oscillibacter sp.

57_20 and Faecalibacterium sp. incertae sedis was tested while conditioning on the visit

variable, using the R package coin (version 1.4.3) with 10,000 permutations. Resulting p-

values were corrected for multiple testing using the Benjamini-Hochberg false discovery rate

(FDR) method.

Statistical significance was defined as $p < 0.05$ or $q < 0.1$, where applicable.

Data and code availability

All code, data, and scripts used in this study have been made publicly available. The code,

scripts   and   processed   raw   data   can   be   accessed   on   Zenodo

(doi: https://doi.org/10.5281/zenodo.15696891). Raw sequencing data will be deposited in

the NCBI database upon publication.

Acknowledgement

We would like to thank Anja Mähler for designing and setting up the LEANER study, for

recruiting the study cohort, the entire study organization and establishing the network

around this fasting study. We thank Alexandra Prüß who assisted as a fasting guide in

carrying out study protocols. We thank Jana Czychi for her excellent technical assistance. This

work was funded by intramural funds of the Experimental and Clinical Research Center, a

cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz

Association and Charité - Universitätsmedizin Berlin; and external funds from the Karl and

Veronica Carstens foundation (KVC 0/120/2021).

FP, NW, HB, DNM, WG and PJO were supported by the BMFTR (Federal Ministry of Research,

Technology and Space), project IDs 01EJ2202A, 01EJ2202D and 01EJ2202B (TAhRget

consortium). FP, NW, and SKF were supported by the European union (HORIZON-HLTH-2022-

STAYHLTH-02, IMMEDIATE consortium). TUPB was supported by the Berlin Center for

Translational Vascular Biomedicine, jointly founded by BIH, Charité - Universitätsmedizin, and

the Max Delbrück Center. DNM and NW were supported by the DZGIF (DZG Innovation

Fund), Topic "Microbiome". SKF, DNM and NW were supported by the German Research

Foundation (DFG), project ID 437531118 (CRC1470, projects A05, A06 and A10). SKF was

supported by the DFG project TRR412 and DZHK. AZ was was supported by the DFG, project

ID 324392634 (TR221).

Author Contributions

CRediT: Conceptualization: TUPB, SB, HB, NS; Data curation: GNK, TUPB, LSB, FG, SB, HB;

Formal Analysis: GNK, TUPB, UL, MM, AK, HB; Funding acquisition: TUPB, NW, PO, WG, DNM,

SKF, SB, HB, NS; Investigation: KK, TS, SK, GR, VM, LB, LM, LSB, FG, FP, SB, NS; Methodology:

GNK, TUPB, UL, WG, PJO, SKF, HB; Project administration: SB, HB, NS; Resources: NW, AZ, PO,

WG, DNM, SKF, SB, HB, NS; Software: GNK, TUPB, UL, AK, SKF; Supervision: TUPB, UL, AZ, PO,

WG, DNM, SKF, SB, HB, NS; Validation: GNK, TUPB, LSB, FG, FP, HB; Visualization: GNK, TUPB,

HB; Writing – original draft: GNK, TUPB, SB, HB, NS; Writing – review & editing: GNK, TUPB,

KK, TS, SK, UL, GR, VM, LB, LM, MM, AK, LSB, FG, FP, NW, AZ, PO, WG, DNM, SKF, SB, HB, NS.

Conflict of interest

NS has received speaker honoraria from Teva GmbH, Alexion Pharma Germany GmbH and

Roche Pharma AG. The other authors declare no competing interests.

Tables

Table 1. Baseline characteristics of healthy participants depending on their randomization to
fasting and waiting control arm. Data are given as means (SD). p-values fasting vs. waiting by
t-test. BMI, body mass index; eGFR, estimated glomerular filtration rate; ALT, alanine
aminotransferase; TSH, thyroid-stimulating hormone; CRP, C-reactive protein; HbA1c,
glycated hemoglobin.

Variable	All	Fasting	Waiting	*P* value
Number (n)	38	19	19	
Sex, female	19 / 38 (50%)	9 / 19 (47%)	10 / 19 (53%)	>0.9
Age (years)	38 (8)	39 (9)	36 (8)	0.4
BMI (kg/m^2)	25.1 (2.5)	25.0 (2.7)	25.2 (2.3)	0.7
eGFR (ml/min/1.73m^2)	102 (14)	98 (12)	106 (15)	0.1
ALT (U/l)	23.1 (8.1)	23.0 (8.2)	23.2 (8.2)	0.2
TSH (mU/l)	1.70 (0.84)	1.77 (0.91)	1.64 (0.77)	0.6
CRP (mg/dl)	0.98 (0.87)	0.78 (0.28)	1.17 (1.17)	0.2
Cholesterol (mg/dl)	182 (36)	189 (35)	175 (36)	0.2
HbA1c (mmol/mol)	33.2 (2.8)	34.2 (2.6)	32.3 (2.7)	0.03
Hemoglobin (g/dl)	14.0 (1.3)	13.8 (1.3)	14.2 (1.2)	0.41
White blood count (uL^{-1})	5.46 (1.02)	5.56 (0.96)	5.37 (1.09)	0.6
Thrombocytes (uL^{-1})	240 (42)	238 (63)	239 (54)	0.9

Figure 1. Physiological effects of prolonged fasting in healthy individuals. a) Schematic

overview of the randomized waitlist-controlled trial. A total of 38 healthy participants were

recruited. The first 19 participants immediately underwent prolonged fasting, while the

remaining 19 served as a waitlist control group. After the initial intervention period, the

waitlist group also underwent the same prolonged fasting protocol, resulting in a complete

dataset of 38 participants undergoing prolonged fasting. The fasting intervention consisted of

a 5-day period with 250 kcal/day, preceded and followed by baseline and follow-up visits at

days 0, 5, and 90. Stool, blood, and clinical data were collected at each visit. The waitlist

group was assessed at an additional baseline (day -90) to control for temporal fluctuations.

b) Glucose time series measured by continuous intradermal monitoring starting one day

prior to fasting (pink) or at baseline for the waiting list control (grey). **c)** Quantification of

absolute changes in mmol/L during the mean daytime (6am to 10pm) glucose levels (top)

and night (10pm to 6am) glucose levels (bottom) as changes compared to the individual

baseline (day 1). Paired t-test with Benjamini-Hochberg false discovery rate correction (BH-

FDR), $*q<0.1$, $**q < 0.01$, $***q < 0.001$. **d)** Resting energy expenditure (REE), **e)** respiratory

exchange ratio (RER), **f)** body mass index (BMI), and **g)** body fat percentage at the different

study visits. Each point represents one participant, lines connect individuals, boxplot (middle)

for all participants, violins (right side) and dots coloured by sex. P-values are from Wilcoxon

signed-rank tests and were corrected using the Holm method.

Figure 2. Prolonged fasting induces transient alterations in gut microbiome composition

and function. a) Alpha diversity as measured by Shannon index for the study visits.

Correlation of Shannon index at baseline with changes in Shannon index immediately **b)**

post-fasting and **c)** at 12-week follow-up, indicating that baseline diversity predicts

microbiome responsiveness. **d)** Principal coordinate analysis (PCoA) based on Bray–Curtis

dissimilarity (naïve, left) and centered on baseline visit for fasting effect and on fasting visit

for post-fasting effect (right) show a transient shift in overall microbial composition after

fasting (pink), which partially reverts at follow-up (blue). Ellipses represent 95% confidence

intervals p-values from PERMANOVA. Dot plots showing differential abundant **e)** species

(taxonomic level) and **f)** gut metabolic modules (functional level). Dots show fasting effects,

follow-up effects and study effects, transparency indicates non-significant findings (q>0.1),

dot size shows absolute Cliff's delta, color shows directionality. Significance by Wilcoxon

signed-rank test with Benjamini–Hochberg false discovery rate correction.

Figure 3. Machine learning model predicts sustained BMI response to prolonged fasting

using clinical and microbiome features. a) Schematic overview of the multi-*omics* feature

selection and classification pipeline. Baseline species abundances, clinical metadata, and

functional modules were used to train a random forest classifier. Important features were

selected through recursive feature elimination, Boruta algorithm, and backward selection. **b)**

Final model includes four top-ranked features: *Faecalibacterium* sp. incertae sedis,

Oscillibacter sp. 57_20, LDL cholesterol, and systolic blood pressure. **c)** Correlation heatmap

of the selected features showing independence from baseline BMI. R-values from Spearman

correlation **d)** Boxplots of the four selected features at baseline, comparing BMI responders

and non-responders, dots show individual patients. P-values by Mann-Whitney-U-test.

Oscilli, *Oscillibacter sp. 57_20*; Faecali, *Faecalibacterium sp.* incertae sedis; LDL, Low-density

lipoprotein cholesterol; sys BP, systolic blood pressure.

Figure 4. Validation of BMI response prediction model in a fasting cohort of patients with metabolic syndrome. a) Schematic of the Maifeld et al. (2021) study: 5-day fasting followed by a DASH diet in individuals with metabolic syndrome (n = 38), with BMI follow-up after 12 weeks. **b)** Receiver operating characteristic (ROC) curve of model performance in the Maifeld cohort, showing good predictive accuracy (AUC = 0.85). **c)** BMI reduction at follow-up of patients classified as responder or non-responder by the prediction model. p-value by one-tailed unpaired t-test. **d)** BMI over the course of the study, split by participants classified as responders or non-responders. Each point represents a participant. P-values are from paired

Wilcoxon signed-rank tests and were corrected for multiple comparisons using the

Benjamini-Hochberg false discovery rate (FDR-BH) method. **e)** Correlation heatmap of model

features (*Oscillibacter sp. 57_20*, *Faecalibacterium sp.* incertae sedis, LDL, systolic blood

pressure) within the Maifeld dataset. Features used for classification at baseline: **f)**

Oscillibacter sp. 57_20, **g)** *Faecalibacterium sp.* incertae sedis, **h)** LDL, and **i)** systolic blood

pressure. Oscilli, *Oscillibacter sp. 57_20*; Faecali, *Faecalibacterium sp.* incertae sedis; LDL,

Low-density lipoprotein cholesterol; sys BP, systolic blood pressure.

Figure 5. Validation of BMI response prediction model in a fasting cohort of patients with multiple sclerosis. a) Schematic of the Bahr et al. (2024) study: two 7-day fasting periods and intermittent fasting in individuals with multiple sclerosis (n = 56), over a 9-month period. **b)** BMI reduction at follow-up of patients classified as responder or non-responder by the prediction model. p-value by one-tailed unpaired t-test. **c)** BMI reduction at follow-up of patients classified as responder or non-responder by the prediction model. p-value by one-tailed unpaired t-test. **d)** BMI over the course of the study, split by participants classified as responders or non-responders. Each point represents a participant. P-values are from paired

Wilcoxon signed-rank tests and were corrected for multiple comparisons using the

Benjamini-Hochberg false discovery rate (FDR-BH) method. **d)** Correlation matrix of selected

features in the Bahr dataset. Features used for classification at baseline: **f)** *Oscillibacter sp.*

57_20, **g)** *Faecalibacterium sp.* incertae sedis, **h)** LDL, and **i)** systolic blood pressure. Oscilli,

Oscillibacter sp. 57_20; Faecali, *Faecalibacterium sp.* incertae sedis; LDL, Low-density

lipoprotein cholesterol; sys BP, systolic blood pressure.

Figure 6. Oscillibacter sp. 57_20 and Faecalibacterium sp. incertae sedis abundance correlates with fecal metabolome. Correlation of Oscillibacter (Oscilli) sp. 57_20 abundance with fecal **a)** glycerol, **b)** methionine, and **c)** uridine levels. Correlation of Faecalibacterium (Faecali) sp. incertae sedis abundance with fecal **d)** butyrate, **e)** tryptophan, and **f)** uridine levels. R-values from Spearman's correlation. P-values from permutation-based independence test screening for associations of species with metabolites while blocking effects of study visits. Abbreviations: Oscilli: *Oscillibacter sp. 57_20*; Faecali: *Faecalibacterium sp.* incertae sedis.

References

1　Di Francesco, A., Di Germanio, C., Bernier, M. & de Cabo, R. A time to fast. *Science*
362, 770-775 (2018). https://doi.org:10.1126/science.aau2095
2　Brandhorst, S. *et al.* Fasting-mimicking diet causes hepatic and blood markers changes
indicating reduced biological age and disease risk. *Nat Commun* **15**, 1309 (2024).
https://doi.org:10.1038/s41467-024-45260-9
3　Gewecke, K. *et al.* Long-term fasting induces a remodelling of fatty acid composition
in erythrocyte membranes. *Eur J Clin Invest*, e14382 (2025).
https://doi.org:10.1111/eci.14382
4　Koppold, D. A. *et al.* International consensus on fasting terminology. *Cell Metab* **36**,
1779-1794 e1774 (2024). https://doi.org:10.1016/j.cmet.2024.06.013
5　Maifeld, A. *et al.* Fasting alters the gut microbiome reducing blood pressure and body
weight in metabolic syndrome patients. *Nat Commun* **12**, 1970 (2021).
https://doi.org:10.1038/s41467-021-22097-0
6　Cignarella, F. *et al.* Intermittent Fasting Confers Protection in CNS Autoimmunity by
Altering the Gut Microbiota. *Cell Metab* **27**, 1222-1235 e1226 (2018).
https://doi.org:10.1016/j.cmet.2018.05.006
7　Choi, I. Y. *et al.* A Diet Mimicking Fasting Promotes Regeneration and Reduces
Autoimmunity and Multiple Sclerosis Symptoms. *Cell Rep* **15**, 2136-2146 (2016).
https://doi.org:10.1016/j.celrep.2016.05.009
8　de Groot, S. *et al.* Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy
for breast cancer in the multicentre randomized phase 2 DIRECT trial. *Nat Commun*
11, 3083 (2020). https://doi.org:10.1038/s41467-020-16138-3
9　Ratiner, K., Ciocan, D., Abdeen, S. K. & Elinav, E. Utilization of the microbiome in
personalized medicine. *Nat Rev Microbiol* **22**, 291-308 (2024).
https://doi.org:10.1038/s41579-023-00998-9
10　von Schwartzenberg, R. J. *et al.* Caloric restriction disrupts the microbiota and
colonization resistance. *Nature* **595**, 272-277 (2021). https://doi.org:10.1038/s41586-
021-03663-4
11　Murthy, V. L. *et al.* Metabolic liability for weight gain in early adulthood. *Cell Rep Med*
5, 101548 (2024). https://doi.org:10.1016/j.xcrm.2024.101548

12   Jiang, Z. *et al.* Human gut microbial aromatic amino acid and related metabolites
prevent obesity through intestinal immune control. *Nat Metab* **7**, 808-822 (2025).
https://doi.org:10.1038/s42255-025-01246-5

13   Hill, D. A. *et al.* Metagenomic analyses reveal antibiotic-induced temporal and spatial
changes in intestinal microbiota with associated alterations in immune cell
homeostasis. *Mucosal Immunol* **3**, 148-158 (2010).
https://doi.org:10.1038/mi.2009.132

14   Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R.
Recognition of commensal microflora by toll-like receptors is required for intestinal
homeostasis. *Cell* **118**, 229-241 (2004). https://doi.org:10.1016/j.cell.2004.07.002

15   Zheng, J. *et al.* Noninvasive, microbiome-based diagnosis of inflammatory bowel
disease. *Nat Med* **30**, 3555-3567 (2024). https://doi.org:10.1038/s41591-024-03280-4

16   Ozarda, Y. *et al.* Protocol and standard operating procedures for common use in a
worldwide multicenter study on reference values. *Clin Chem Lab Med* **51**, 1027-1040
(2013). https://doi.org:10.1515/cclm-2013-0249

17   Bahr, L. S. *et al.* Fasting, ketogenic and anti-inflammatory diets stabilized active
relapsing-remitting multiple sclerosis over 18 months – a randomized, controlled
study. *medRxiv*, 2024.2008.2013.24311863 (2024).
https://doi.org:10.1101/2024.08.13.24311863

18   Hothorn, T., Hornik, K., van de Wiel, M. A. & Zeileis, A. Implementing a Class of
Permutation Tests: The coin Package. *Journal of Statistical Software* **28**, 1 - 23 (2008).
https://doi.org:10.18637/jss.v028.i08

19   Berry, S. E. *et al.* Human postprandial responses to food and potential for precision
nutrition. *Nat Med* **26**, 964-973 (2020). https://doi.org:10.1038/s41591-020-0934-0

20   Zeevi, D. *et al.* Personalized Nutrition by Prediction of Glycemic Responses. *Cell* **163**,
1079-1094 (2015). https://doi.org:10.1016/j.cell.2015.11.001

21   Horton, T. J. & Hill, J. O. Prolonged fasting significantly changes nutrient oxidation and
glucose tolerance after a normal mixed meal. *J Appl Physiol (1985)* **90**, 155-163
(2001). https://doi.org:10.1152/jappl.2001.90.1.155

22   Solianik, R., Zidoniene, K., Eimantas, N. & Brazaitis, M. Prolonged fasting outperforms
short-term fasting in terms of glucose tolerance and insulin release: a randomised

controlled trial. *Br J Nutr* **130**, 1500-1509 (2023).
https://doi.org:10.1017/S0007114523000557

23 Laurens, C. *et al.* Is muscle and protein loss relevant in long-term fasting in healthy
men? A prospective trial on physiological adaptations. *J Cachexia Sarcopenia Muscle*
12, 1690-1703 (2021). https://doi.org:10.1002/jcsm.12766

24 Dai, Z. *et al.* Effects of 10-Day Complete Fasting on Physiological Homeostasis,
Nutrition and Health Markers in Male Adults. *Nutrients* **14** (2022).
https://doi.org:10.3390/nu14183860

25 Triffoni-Melo, A. T., Suen, V. M. M., Resende, C. M. M., Braga, C. B. M. & Diez-Garcia,
R. W. Resting energy expenditure adaptation after short-term caloric restriction in
morbidly obese women. *Rev Nutr* **28**, 505-511 (2015). https://doi.org:10.1590/1415-
52732015000500005

26 Schlogl, M. *et al.* Energy Expenditure Responses to Fasting and Overfeeding Identify
Phenotypes Associated With Weight Change. *Diabetes* **64**, 3680-3689 (2015).
https://doi.org:10.2337/db15-0382

27 Mohr, A. E. *et al.* Gut microbiome remodeling and metabolomic profile improves in
response to protein pacing with intermittent fasting versus continuous caloric
restriction. *Nat Commun* **15**, 4155 (2024). https://doi.org:10.1038/s41467-024-
48355-5

28 Ducarmon, Q. *et al.* Long-term fasting remodels gut microbial metabolism and host
metabolism. *bioRxiv*, 2024.2004.2019.590209 (2024).
https://doi.org:10.1101/2024.04.19.590209

29 Wang, Y. C. *et al.* Indole-3-Propionic Acid Protects Against Heart Failure With
Preserved Ejection Fraction. *Circ Res* **134**, 371-389 (2024).
https://doi.org:10.1161/CIRCRESAHA.123.322381

30 Barcenilla, A. *et al.* Phylogenetic relationships of butyrate-producing bacteria from
the human gut. *Appl Environ Microbiol* **66**, 1654-1661 (2000).
https://doi.org:10.1128/AEM.66.4.1654-1661.2000

31 Essex, M. *et al.* Gut microbiota dysbiosis is associated with altered tryptophan
metabolism and dysregulated inflammatory response in COVID-19. *NPJ Biofilms*
Microbiomes **10**, 66 (2024). https://doi.org:10.1038/s41522-024-00538-0

32　Roager, H. M. & Licht, T. R. Microbial tryptophan catabolites in health and disease.

Nat Commun **9**, 3294 (2018). https://doi.org:10.1038/s41467-018-05470-4

33　Hanssen, R. *et al.* Circulating uridine dynamically and adaptively regulates food intake

in humans. *Cell Rep Med* **4**, 100897 (2023).

https://doi.org:10.1016/j.xcrm.2022.100897

34　Deng, Y. *et al.* An adipo-biliary-uridine axis that regulates energy homeostasis. *Science*

355 (2017). https://doi.org:10.1126/science.aaf5375

35　Steculorum, S. M. *et al.* Hypothalamic UDP Increases in Obesity and Promotes

Feeding via P2Y6-Dependent Activation of AgRP Neurons. *Cell* **162**, 1404-1417 (2015).

https://doi.org:10.1016/j.cell.2015.08.032

36　Deng, Y. *et al.* Adipocyte Xbp1s overexpression drives uridine production and reduces

obesity. *Mol Metab* **11**, 1-17 (2018). https://doi.org:10.1016/j.molmet.2018.02.013

37　Han, H. *et al.* From gut microbiota to host appetite: gut microbiota-derived

metabolites as key regulators. *Microbiome* **9**, 162 (2021).

https://doi.org:10.1186/s40168-021-01093-y

38　Ali, I. *et al.* Ramadan Fasting Leads to Shifts in Human Gut Microbiota Structured by

Dietary Composition. *Front Microbiol* **12**, 642999 (2021).

https://doi.org:10.3389/fmicb.2021.642999

39　Lopez-Siles, M., Duncan, S. H., Garcia-Gil, L. J. & Martinez-Medina, M.

Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. *ISME*

J **11**, 841-852 (2017). https://doi.org:10.1038/ismej.2016.176

40　Remely, M. *et al.* Increased gut microbiota diversity and abundance of

Faecalibacterium prausnitzii and Akkermansia after fasting: a pilot study. *Wien Klin*

Wochenschr **127**, 394-398 (2015). https://doi.org:10.1007/s00508-015-0755-1

41　Guo, Y. *et al.* Intermittent Fasting Improves Cardiometabolic Risk Factors and Alters

Gut Microbiota in Metabolic Syndrome Patients. *J Clin Endocrinol Metab* **106**, 64-79

(2021). https://doi.org:10.1210/clinem/dgaa644

42　Mesnage, R., Grundler, F., Schwiertz, A., Le Maho, Y. & Wilhelmi de Toledo, F. Changes

in human gut microbiota composition are linked to the energy metabolic switch

during 10 d of Buchinger fasting. *J Nutr Sci* **8**, e36 (2019).

https://doi.org:10.1017/jns.2019.33

43　Ozkul, C., Yalinay, M. & Karakan, T. Structural changes in gut microbiome after
Ramadan fasting: a pilot study. *Benef Microbes* **11**, 227-233 (2020).
https://doi.org:10.3920/BM2019.0039
44　Sinha, A. K. *et al.* Dietary fibre directs microbial tryptophan metabolism via metabolic
interactions in the gut microbiota. *Nat Microbiol* **9**, 1964-1978 (2024).
https://doi.org:10.1038/s41564-024-01737-3
45　Fassarella, M. *et al.* Gut microbiome stability and resilience: elucidating the response
to perturbations in order to modulate gut health. *Gut* **70**, 595-605 (2021).
https://doi.org:10.1136/gutjnl-2020-321747
46　Khan, M. N. *et al.* Intermittent fasting positively modulates human gut microbial
diversity and ameliorates blood lipid profile. *Front Microbiol* **13**, 922727 (2022).
https://doi.org:10.3389/fmicb.2022.922727
47　Rajput, D., Wang, W. J. & Chen, C. C. Evaluation of a decided sample size in machine
learning applications. *BMC Bioinformatics* **24**, 48 (2023).
https://doi.org:10.1186/s12859-023-05156-9
48　Birkenbihl, C. *et al.* Differences in cohort study data affect external validation of
artificial intelligence models for predictive diagnostics of dementia - lessons for
translation into clinical practice. *EPMA J* **11**, 367-376 (2020).
https://doi.org:10.1007/s13167-020-00216-z
49　Harris, P. A. *et al.* The REDCap consortium: Building an international community of
software platform partners. *J Biomed Inform* **95**, 103208 (2019).
https://doi.org:10.1016/j.jbi.2019.103208
50　Harris, P. A. *et al.* Research electronic data capture (REDCap)--a metadata-driven
methodology and workflow process for providing translational research informatics
support. *J Biomed Inform* **42**, 377-381 (2009).
https://doi.org:10.1016/j.jbi.2008.08.010
51　Mahler, A. *et al.* Increased Salt Intake Decreases Diet-Induced Thermogenesis in
Healthy Volunteers: A Randomized Placebo-Controlled Study. *Nutrients* **14** (2022).
https://doi.org:10.3390/nu14020253
52　Bartolomaeus, T. U. P. *et al.* Quantifying technical confounders in microbiome studies.
Cardiovasc Res **117**, 863-875 (2021). https://doi.org:10.1093/cvr/cvaa128
898